Dianthus Therapeutics
DNTH
53 hedge funds and large institutions have $11.1M invested in Dianthus Therapeutics in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 15 reducing their positions, and 25 closing their positions.
400% more call options, than puts
Call options by funds: $10K | Put options by funds: $2K
7% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 15
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.39% less ownership
Funds ownership: 5.3% → 2.9% (-2.4%)
26% less funds holding
Funds holding: 72 → 53 (-19)
76% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 25
84% less capital invested
Capital invested by funds: $67.4M → $11.1M (-$56.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HJMC
Hellman Jordan Management Company
Quincy,
Massachusetts
|
+$287K |
| 2 |
Millennium Management
New York
|
+$241K |
| 3 |
Renaissance Technologies
New York
|
+$203K |
| 4 |
LSA
Leonteq Securities AG
Zurich,
Switzerland
|
+$199K |
| 5 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$143K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$9.5M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$5.06M |
| 3 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$3M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$2.61M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$1.84M |
DNTH Hedge Fund Activity: Q4 2022 in Review
53 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q4 2022, worth a combined $11.1M — down 84% from $67.4M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of DNTH and 6 opened new positions — a net loss of 19 holders — while 15 trimmed existing stakes and 16 added.
The largest buyer was Hellman Jordan Management Company, adding an estimated $287K. The largest seller was Janus Henderson Group, exiting entirely with an estimated $9.5M sold.
- 53 institutional investors held Dianthus Therapeutics (DNTH) as of Q4 2022, down from 72 in Q3 2022.
- Funds reported $11.1M of Dianthus Therapeutics stock for Q4 2022, down 84% quarter-over-quarter.
- 6 funds opened new Dianthus Therapeutics positions in Q4 2022 and 25 closed out, a net change of -19 holders.
- The largest Dianthus Therapeutics buyer in Q4 2022 was Hellman Jordan Management Company, an estimated $287K added.
- The largest Dianthus Therapeutics seller in Q4 2022 was Janus Henderson Group, an estimated $9.5M sold.
Based on aggregated 13F filings for Q4 2022.